Skip to main content
Premium Trial:

Request an Annual Quote

Helomics, ChemImage Partner on Prostate Cancer Monitoring Tech Development

NEW YORK — Predictive Oncology, formerly Precision Therapeutics, said today that its Helomics subsidiary has partnered with molecular imaging firm ChemImage to develop technology for monitoring how prostate cancer responds to treatment.

Under the terms of the agreement, ChemImage will provide Helomics with a set of human prostate biopsy and prostatectomy tissue samples for sequencing. Helomics will integrate the sequencing results and existing Raman spectroscopy data on the samples into its D-CHIP — or Dynamic Clinical Health Insights — artificial intelligence (AI) knowledgebase with the goal of building a predictive model of prostate cancer drug response.

Additional terms of the deal between the Pittsburgh-based companies was not disclosed.

"We believe that alliances of this kind are an excellent opportunity to demonstrate the power of the multi-omic approach coupled to AI with the goal of building predictive models for identifying and treating patients at higher risk," Helomics CTO Mark Collins said in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.